H. Y. Chu

The paper shows that muscarinic acetylcholine receptors in dermal papilla cells regulate hair growth through Wnt/β-catenin signaling activation.

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

This study identifies four broad, potent monoclonal antibodies against SARS-CoV-2 spike protein that neutralize multiple variants, including Omicron and XBB.1.5, targeting conserved regions with high functional constraint.

This study shows that RBD antibodies contribute more to SARS-CoV-2 neutralization when target cells have high ACE2 expression, highlighting ACE2 levels as a critical experimental factor.

This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.

The paper examines the antibody response to the SARS-CoV-2 Delta variant, showing it targets class 1 and 2 epitopes more than class 3, and that mutations in these regions reduce antibody binding.

This study characterizes antibody responses to SARS-CoV-2 Spike protein after infection and vaccination, identifying epitope binding patterns and escape mutation profiles.

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.

This study compares SARS-CoV-2 Spike antibody responses between macaques and humans after vaccination or infection, identifying shared and distinct epitope recognition patterns and escape pathways.

This study compares antibody responses to early SARS-CoV-2 isolates and the B.1.351 variant, finding shifts in immunodominance hierarchy within the spike receptor-binding domain.

The paper compares the specificity of antibodies from the mRNA-1273 vaccine and natural infection, finding vaccine antibodies are more RBD-focused but have broader epitope coverage within the RBD.

This study maps mutations in the SARS-CoV-2 RBD that affect recognition by polyclonal human serum antibodies, identifying key sites like E484 that significantly reduce neutralization.

This study identifies antibody escape pathways for SARS-CoV-2 spike protein using Phage-DMS, revealing variable escape mutations in immunodominant regions and individual epitope targeting differences.

This study maps SARS-CoV-2 antibody epitopes and identifies cross-reactive sequences with endemic HCoVs in COVID-19 patients.

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

This study characterizes neutralizing antibodies from a SARS-CoV-2 infected individual, finding that most antibodies are non-neutralizing and target epitopes outside the RBD, while two potent neutralizers bind the RBD with minimal mutation.

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

This paper provides a protocol for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein to measure neutralizing antibody activity in a luciferase-based assay.